IRF2BP1

Across TCGA pan-cancer cohorts, IRF2BP1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated IRF2BP1 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IRF2BP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IRF2BP1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, UCEC, and CCRCC are the cancer types where IRF2BP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.802	0.983	<.001	46	view →
UCEC	OS	Median	II,III,IV	0.609	1.000	.008	24	view →
CCRCC	DFS	Quartile	III,IV	0.894	0.447	.021	12	view →
LUAD	OS	Tertile	All	1.000	0.768	.022	11	view →
GBM	OS	Tertile	All	0.599	0.277	.010	8	view →
PDAC	OS	Median	IV	0.951	0.381	.006	6	view →
LSCC	DFS	Quartile	All	0.854	0.569	.027	6	view →
OV	DFS	Median	All	0.713	1.000	.046	4	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

IRF2BP1–HNSC (OS)

Open the HNSC breakdown →